|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119456 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-27 11:18:16 |
|
注册时间: Date of Registration: |
2026-02-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
评价胸腹腔内窥镜单孔手术系统远程手术的安全性和有效性的前瞻性、多中心、单组目标值临床试验 |
|
Public title: |
A prospective, multicenter, single-arm study evaluating the safety and efficacy of telesurgery Using SHURUI Single-Port Robotic System |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
评价胸腹腔内窥镜单孔手术系统远程手术的安全性和有效性的前瞻性、多中心、单组目标值临床试验 |
|
Scientific title: |
A prospective, multicenter, single-arm study evaluating the safety and efficacy of telesurgery Using SHURUI Single-Port Robotic System |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘开明 |
研究负责人: |
赵任 |
|
Applicant: |
Kaiming Liu |
Study leader: |
Ren Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 189 1601 3760 |
研究负责人电话:
Study leader's |
+86 21 6437 0045 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
kaiming.liu@surgerii.com |
研究负责人电子邮件: Study leader's E-mail: |
1217909635@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区永泰庄北路1号 |
研究负责人通讯地址: |
上海市嘉定区希望路999号 |
|
Applicant address: |
No.1 Yongtaizhuang Road North, Haidian District, Beijing |
Study leader's address: |
No.999 Hope Road, Jiading District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京术锐机器人股份有限公司 |
||
|
Applicant's institution: |
Beijing Surgerii Robotics Company Limited |
||
|
研究负责人所在单位: |
上海交通大学医学院附属瑞金医院(北院) |
||
|
Affiliation of the Leader: |
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine (North Hospital) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)伦审第(162)号a |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属瑞金医院试验伦理委员会 |
||
|
Name of the ethic committee: |
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-14 00:00:00 | ||
|
伦理委员会联系人: |
刘海莉 |
||
|
Contact Name of the ethic committee: |
Haili Liu |
||
|
伦理委员会联系地址: |
上海市黄浦区瑞金二路197号 |
||
|
Contact Address of the ethic committee: |
No.197 Ruijin Second Road, Huangpu District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 8058 1800 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院(北院) |
||||||||||||||||||||||
|
Primary sponsor: |
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine (North Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市嘉定区希望路999号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.999 Hope Road, Jiading District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
申办方 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sponsor |
||||||||||||||||||||||
|
研究疾病: |
消化系统疾病、泌尿生殖系统疾病、呼吸系统疾病 |
||||||||||||||||||||||
|
Target disease: |
Disease of Digestive System/Urogenital System/Respiratory System |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价胸腹腔内窥镜单孔手术系统远程手术的安全性和有效性的前瞻性、多中心、单组目标值临床试验 |
||||||||||||||||||||||
|
Objectives of Study: |
A prospective, multicenter, single-arm study evaluating the safety and efficacy of telesurgery Using SHURUI Single-Port Robotic System |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.18~80周岁(含18,80周岁),性别不限; 2.拟接受胸腹腔内窥镜手术系统辅助进行以下任一手术者: (1) 子宫切除术加盆腔淋巴结清扫术等妇科手术者: (2) 肾部分切除术、根治性前列腺切除术等泌尿外科手术者: (3) 远端胃癌根治术、结直肠癌根治术、肝切除术/脾切除术等普通外科手术者: (4) 肺段/肺叶切除术、食管癌根治术等胸外科手术者; (5) 其他经研究者判断具有胸腹腔内窥镜手术治疗指征者。 3.受试者充分了解本试验的受益和风险,愿意参加本试验并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged 18-80 years old, and gender is not limited; 2. Those who are scheduled to undergo any of the following surgeries assisted by the SHURUI Single-Port Robotic System: (1) Gynecological surgeries such as hysterectomy with pelvic lymph node dissection, etc. (2) Urological surgeries such as partial nephrectomy, radical prostatectomy, etc. (3) General surgical procedures such as radical gastrectomy for distal gastric cancer, radical resection of colorectal cancer, hepatectomy/splenectomy, etc. (4) Thoracic surgeries such as segmentectomy/lobectomy, radical resection of esophageal cancer, etc. (5) Others who, as judged by the researcher, have indications for thoracoabdominal endoscopic surgery. 3. Patients fully understand the benefits and risks of this trial, and are willing to participate in this trial and sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.心、肺、脑、肝、肾疾病等严重合并症,不能耐受手术或麻醉; 2.严重贫血、凝血功能障碍; 3.合并手术部位或全身性感染、严重炎症反应; 4.妊娠和哺乳期妇女; 5.癫痫或精神病史; 6.既往手术史怀疑术区严重粘连影响手术者; 7.BMI ≥ 30 kg/m^2 拟行腹部手术的重度肥胖者; 8.术前3个月以内参加过其它任何药物或医疗器械临床试验; 9.研究者认为不适合参加本临床试验的其他情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Have severe heart, lung, brain, liver and kidney diseases, unable to tolerate surgery or anesthesia; 2. Inability to tolerate pneumoperitoneum; 3. Severe anemia, coagulation dysfunction; 4. Pregnant and lactating women; 5. Those with a history of epilepsy or psychiatric illness; 6. Extensive metastasis in the abdomen-pelvic cavity of the tumor; 7. Severe obesity with BMI >= 30 kg/m^2 8. Participated in clinical trials of other drugs or devices within 3 months before surgery; 9. Other conditions deemed unsuitable by the investigator to participate in this trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-25 00:00:00至 To 2027-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-02 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
None |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |